Growth Metrics

Palvella Therapeutics (PVLA) Shares Outstanding (Weighted Average) (2013 - 2026)

Palvella Therapeutics (PVLA) reported Shares Outstanding (Weighted Average) of $13.1 million for Q1 2026, up 18.81% year-over-year from $11.0 million in Q1 2025, and up 16.3% on a QoQ basis from $11.3 million in Q4 2025.

Palvella Therapeutics (PVLA) has 14 years of Shares Outstanding (Weighted Average) data on file, last reported at $13.1 million in Q1 2026.

  • Quarterly Shares Outstanding (Weighted Average) rose 18.81% year-over-year to $13.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.1 million (up 18.81% YoY) and the FY2025 annual result came in at $11.3 million, up 405.46% from the prior year.
  • Shares Outstanding (Weighted Average) advanced to $13.1 million in Q1 2026 per PVLA's latest filing, from $11.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $74.4 million in Q3 2022 and bottomed at $100000.0 in Q3 2024.
  • The 5-year median for Shares Outstanding (Weighted Average) is $11.0 million (2025), against an average of $21.5 million.
  • The widest annual swing landed in 2023, when Shares Outstanding (Weighted Average) tumbled 98.74%; it then surged 10943.76% in 2025.
  • Tracing PVLA's Shares Outstanding (Weighted Average) over 5 years: stood at $74.2 million in 2022, then sank by 97.61% to $1.8 million in 2023, then climbed by 25.75% to $2.2 million in 2024, then surged by 405.46% to $11.3 million in 2025, then climbed by 16.3% to $13.1 million in 2026.
  • Per Business Quant, the three latest PVLA Shares Outstanding (Weighted Average) figures stand at $13.1 million (Q1 2026), $11.3 million (Q4 2025), and $11.0 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares (Weighted Avg.) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 177,333.76 Bn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 185,491.37 Bn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 100.00 Bn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 55.66 Bn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 118.76 Bn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 254.10 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - 16.04 Bn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 104.00 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 132.89 Mn
10 Palvella Therapeutics 1.47 Bn 1.21 Bn - 13.09 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 13.09 Mn
Dec 31, 2025 11.25 Mn
Sep 30, 2025 11.04 Mn
Jun 30, 2025 11.05 Mn
Mar 31, 2025 11.01 Mn
Dec 31, 2024 2.23 Mn
Sep 30, 2024 100,000.00
Jun 30, 2024 1.77 Mn
Mar 31, 2024 1.77 Mn
Dec 31, 2023 1.77 Mn
Sep 30, 2023 1.24 Mn
Jun 30, 2023 1.10 Mn
Mar 31, 2023 931,000.00
Dec 31, 2022 74.17 Mn
Sep 30, 2022 74.40 Mn
Jun 30, 2022 74.13 Mn
Mar 31, 2022 73.71 Mn
Dec 31, 2021 64.55 Mn
Sep 30, 2021 67.73 Mn
Jun 30, 2021 61.91 Mn
Mar 31, 2021 56.30 Mn
Dec 31, 2020 54.48 Mn
Sep 30, 2020 54.34 Mn
Jun 30, 2020 53.79 Mn
Mar 31, 2020 55.21 Mn
Dec 31, 2019 50.63 Mn
Sep 30, 2019 49.35 Mn
Jun 30, 2019 49.20 Mn
Mar 31, 2019 50.87 Mn
Dec 31, 2018 53.08 Mn
Sep 30, 2018 54.09 Mn
Jun 30, 2018 53.98 Mn
Mar 31, 2018 50.05 Mn
Dec 31, 2017 43.93 Mn
Sep 30, 2017 43.62 Mn
Jun 30, 2017 43.24 Mn
Mar 31, 2017 43.06 Mn
Dec 31, 2016 41.71 Mn
Sep 30, 2016 43.06 Mn
Jun 30, 2016 40.86 Mn
Mar 31, 2016 39.83 Mn
Dec 31, 2015 34.39 Mn
Sep 30, 2015 38.89 Mn
Jun 30, 2015 29.43 Mn
Mar 31, 2015 29.29 Mn
Dec 31, 2014 13.87 Mn
Sep 30, 2014 5.00 Mn
Jun 30, 2014 11.83 Mn
Mar 31, 2014 11.83 Mn
Dec 31, 2013 11.83 Mn
Sep 30, 2013 6.10 Mn
Jun 30, 2013 5.00 Mn